Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
Authors' conclusion
The model predicted that all doses of tirzepatide represent cost-effective alternatives to LSM for management of overweight and obesity at a willingness-to-pay threshold of $150,000 per QALY.
Study context
- Population
- Simulated adult patients with overweight or obesity; short-term outcomes from SURMOUNT-1 linked to obesity-related complications (CV events, T2D onset, cancer, osteoarthritis, sleep apnea)
- Participants
- 1,000 simulated patients
- Comparison
- Tirzepatide vs lifestyle modification
- Outcome
- Incremental QALYs, costs and incremental cost-effectiveness ratios vs LSM
- Follow-up
- Lifetime
Methodological detailsindividual-level discrete event simulation, lifetime time horizon, 3% annual discount rate, direct medical costs only
- Individual-level discrete event simulation
- Lifetime time horizon
- 3% annual discount rate
- Direct medical costs only
Main finding
As reported in the abstract
Incremental QALYs, costs and ICER vs LSM
| Group | Additional quality-adjusted life years (QALYs) | Additional costs | ICER per QALY gained |
|---|---|---|---|
| Tirzepatide 5 mg | 0.54 | $79,288 | $146,331 |
| Tirzepatide 10 mg | 0.55 | $70,453 | $127,644 |
| Tirzepatide 15 mg | 0.61 | $75,839 | $125,053 |
Additional quality-adjusted life years (QALYs)
Tirzepatide 5 mg0.54
Tirzepatide 10 mg0.55
Tirzepatide 15 mg0.61
Additional costs
Tirzepatide 5 mg$79,288
Tirzepatide 10 mg$70,453
Tirzepatide 15 mg$75,839
ICER per QALY gained
Tirzepatide 5 mg$146,331
Tirzepatide 10 mg$127,644
Tirzepatide 15 mg$125,053
Original publication
Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. Obesity (Silver Spring). Published 13 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →